In partnership with
Anna's Daybreak News
Just facts, you think for yourself
Tuesday, 5:10 AM
April 28, 2026
Good morning news friend! Discover today’s defining stories and the future they set in motion. 📰🌟
Notice: If you’re reading this email in the Gmail app, you will not be able to see both of our health articles at the bottom. 👉 Click here to view the full newsletter online — it’s free and easy to read.
King Charles Visit
King Charles III begins a four-day visit to Washington D.C. to mark 250 years since U.S. independence and ease tensions with the Trump administration.
His itinerary includes a speech to Congress—the first by a British monarch since 1991—a private meeting with President Trump, and a state dinner.
Tensions stem from Trump’s criticism of UK leadership over Iran strikes, NATO disputes, and unresolved trade and military cooperation issues.
Security is heightened after a recent White House event shooting. The visit aims to stabilize the "Special Relationship" amid political friction. Charles will also visit New York’s 9/11 memorial and travel to Bermuda, the first British monarch visit to that territory.
Sources: Reuters, AP News, Itv, WallStreetJournal
Do you believe King Charles III’s visit to the U.S. will significantly improve U.S.-U.K. relations?
Diane lost 38 pounds.
She felt incredible. Her knees stopped clicking. Her blood sugar stabilized. She was the GLP-1 success story we all see on Instagram.
Then her insurance changed, the price hit $1,349 a month, and she stopped.
A year later, she’d regained 22 pounds. But when she tried to open a stuck jar of pickles—something she used to do without thinking—she couldn't budge it.
Diane isn't just "aging." She’s sarcopenic-in-progress.
She fell into the trap that is about to hit millions of Americans in their 40s and 50s. The scale tells one story, but her muscle tells another.
If you’re over 40, your skeletal muscle is the only thing keeping you independent for the next 30 years. And the "cycle"—going on these drugs, quitting, and restarting—is quietly stealing a decade of your strength in a single year.
We’ve pulled back the curtain on the "40+ Body Composition Lock." It’s a protocol to use these drugs without trading your future for a smaller waistline today.
The Pickle Jar Moment: The 74% Problem
Most people think they’ll stay on Ozempic forever. They won't. Fewer than one in four stay on for a year. We look at why the "restart" intent is so high and why each loop makes your body composition worse than when you started.
[Section 1: The Invisible Decline]
The Math of Decay: 10 Years in 12 Months
When you lose 50 pounds on a GLP-1, you might be losing 20 pounds of lean tissue. For a 60-year-old, that’s equivalent to ten years of natural aging compressed into one quarter. We break down the DXA numbers that actually matter.
[Section 2: What is Actually Breaking]
The Asymmetry Trap: Why the Regain is Poison
Regained weight is almost entirely fat. Muscle requires years of load and protein to build back; fat requires a few months of pizza. We explain the "Cycling Pattern" that leaves you at your starting weight but with 8 pounds less muscle and 8 pounds more fat.
[Section 3: Why the Scale is Lying]
The $149 Pill: Why the Trap is Scaling
The "Needle Barrier" is gone. With the FDA approval of Foundayo (the first oral GLP-1 pill) and $149/month pricing from Amazon, everyone is about to get a prescription. We look at why this "frictionless" access is a musculoskeletal disaster waiting to happen.
[Section 4: The Oral Wave]
The 40+ Body Composition Lock: The 5-Step Protocol
This is the system. Five steps. No fluff. We give you the exact protein math (hint: the RDA is obsolete), the "Minimum Effective Dose" for lifting, and the off-ramp plan you need before you take your first dose.
[Section 5: The Proprietary System]
The Five Mistakes: Why Cardio is Making it Worse
Most people eat less and run more. In a GLP-1 deficit, that is the fastest way to melt your muscle. We look at the "Anti-Patterns" like underdosing protein and skipping the $42 scan that could save your independence.
[Section 6: The Errors that Cost You]
The Quiet Payoff: The Next 30 Years
Sarcopenia used to be invisible until you fell and couldn't get up. Now, it has a name and a number. We show you how to build a dashboard that protects your grip, your gait, and your freedom.
[Section 7: The Dashboard]
The drugs aren't the enemy. The cycle is.
If you don't have a protocol, you're playing a dangerous game with your own longevity.
Get the full playbook.
Iranian Peace Proposal
Iran offered to end attacks on ships in the Strait of Hormuz if the U.S. lifts its naval blockade and delays nuclear talks.
Iran’s Foreign Minister met Putin, who pledged Russian support and praised Iran's resistance. President Trump insisted any deal must prevent Iran from acquiring nuclear weapons and suggested talks might be remote.
The conflict has killed over 3,000 in Iran, 2,500 in Lebanon, and dozens in Israel, the Gulf, and U.S. forces. Iran’s Revolutionary Guard seized two container ships and proposed tolling the strait with Oman.
Oil prices rose 2.4% to $107.84 a barrel amid supply disruptions. Germany criticized the U.S. strategy, while Gulf oil exports are expected to normalize by late June.
Sources: WallStreetJournal, AP News, Bloomberg, Reuters
Do you think the US should accept Iran's peace plan?
OpenAI Shakes Off Microsoft
OpenAI and Microsoft restructured their partnership in April 2026, allowing OpenAI to sell AI products on any cloud platform, including Amazon and Google, while Microsoft remains the primary cloud provider with first-release rights on Azure unless it opts out.
Microsoft’s exclusive license to OpenAI’s IP ends, retaining a non-exclusive license through 2032. OpenAI will pay Microsoft about 20% revenue share capped through 2030; Microsoft will stop paying OpenAI.
Microsoft invested over $13 billion, owning 27% of OpenAI. OpenAI is expanding deals, including $100 billion with AWS. The AGI-related exclusivity clause is removed.
Both companies continue collaboration in data centers and cybersecurity. Microsoft’s shares fell 1%. OpenAI may IPO in 2026.
Sources: Reuters, AP News, Openai, WallStreetJournal, CNBC
Will OpenAI’s decision to expand partnerships beyond Microsoft eventually weaken Microsoft’s influence in the AI market?
China Hits Meta
China ordered Meta to cancel its $2 billion acquisition of AI startup Manus, citing a 15-year-old foreign investment review law.
Manus, founded in China and now based in Singapore, develops autonomous AI agents. Regulators demanded withdrawal four months after the deal closed, reflecting concerns over advanced tech transfers amid US-China tensions.
Meta said it complied with laws and expected resolution; Manus employees joined Meta’s AI teams. China’s move follows prior tech crackdowns like Didi’s NYSE delisting and Ant Group’s IPO block.
The ruling warns Chinese startups against relocating abroad to evade scrutiny. The case precedes a US-China summit addressing technology and trade issues.
Sources: Bloomberg, AP News, Reuters, BBC, Investmentmonitor
Do you believe countries should have the authority to block completed foreign acquisitions for national security reasons?
Click here to read the poll results and comments from our previous edition. Over 3,443 people gave their opinion about how long the conflict in Iran will last and more.
Cat Cravings Unveiled
Researchers studied 12 cats after a 16-hour fast; only 4 ate a full 20-gram meal in 10 minutes, with most stopping after one-third.
Six dry foods with distinct odors were tested. Cats ate less with repeated exposure to the same food but increased intake when given different foods or odors.
Olfactory habituation, called sensory-specific satiety, causes cats to stop eating due to familiarity with food scent, not fullness. Changing food odor renewed appetite, unlike in dogs.
This insight could help manage feline obesity or stimulate appetite in ill or aging cats by varying food odors.
Sources: Sciencealert
Would you think that changing only the scent of a cat’s regular food could significantly increase its willingness to eat?
Autism Links Uncovered
A study of 6.14 million U.S. births (2014-2023) linked prenatal exposure to 15 cholesterol-disrupting drugs—including antidepressants, antipsychotics, beta-blockers, and statins—to increased autism risk.
Mothers taking these drugs had a 1.47 times higher chance of having a child with autism spectrum disorder (ASD). Each additional drug raised risk by 1.33 times; four or more drugs increased it 2.33 times.
Use of these medications during pregnancy rose from 4.6% in 2014 to 16.8% in 2023. Cholesterol is crucial for fetal brain development, and disruption is linked to conditions like Smith-Lemli-Opitz syndrome, which shows ASD traits in 75% of cases. Researchers call for safer prescribing and further study.
Sources: SciTechDaily
Do you think the potential increased risk of autism from these medications outweighs the benefits they provide to the mother’s health during pregnancy?
“Leave the Oddities to the Circus. You ought to make it a firm rule never to act the part of a blazing eccentric, neither by putting on a deliberate, showboating performance, nor by just being too careless to behave like a civilized human being.”
Information is free. Intelligence is scarce.
You are one of 550,000 readers receiving this briefing. That is a crowd.
To join the 1,800 investors who receive our redacted contract briefings and wealth defense protocols, you need to step behind the velvet rope.
Join the Inner Circle.
Baked with love,
Anna Eisenberg ❤️